These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 18242386)
1. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386 [TBL] [Abstract][Full Text] [Related]
2. Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines. Noda M; Tatsumi Y; Tomizawa M; Takama T; Mitsufuji S; Sugihara H; Kashima K; Hattori T J Gastroenterol; 2002; 37(11):896-904. PubMed ID: 12483244 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Shigemura K; Shirakawa T; Wada Y; Kamidono S; Fujisawa M; Gotoh A Urology; 2005 Dec; 66(6):1239-44. PubMed ID: 16360450 [TBL] [Abstract][Full Text] [Related]
4. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520 [TBL] [Abstract][Full Text] [Related]
5. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Hasegawa K; Ohashi Y; Ishikawa K; Yasue A; Kato R; Achiwa Y; Nishio E; Udagawa Y Int J Oncol; 2005 May; 26(5):1419-28. PubMed ID: 15809736 [TBL] [Abstract][Full Text] [Related]
6. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602 [TBL] [Abstract][Full Text] [Related]
7. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837 [TBL] [Abstract][Full Text] [Related]
10. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755 [TBL] [Abstract][Full Text] [Related]
11. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]. Zhan J; Tang XD Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218 [TBL] [Abstract][Full Text] [Related]
12. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ. Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871 [TBL] [Abstract][Full Text] [Related]
13. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Lampiasi N; FoderĂ D; D'Alessandro N; Cusimano A; Azzolina A; Tripodo C; Florena AM; Minervini MI; Notarbartolo M; Montalto G; Cervello M Int J Mol Med; 2006 Feb; 17(2):245-52. PubMed ID: 16391822 [TBL] [Abstract][Full Text] [Related]
14. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472 [TBL] [Abstract][Full Text] [Related]
15. Dominant role of E-cadherin in the progression of bladder cancer. Imao T; Koshida K; Endo Y; Uchibayashi T; Sasaki T; Namiki M J Urol; 1999 Feb; 161(2):692-8. PubMed ID: 9915485 [TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695 [TBL] [Abstract][Full Text] [Related]
17. Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Matsunaga N; Yamada N; Ohira M; Tachimori A; Nishiguchi Y; Nishino H; Seki S; Hirakawa K Oncol Rep; 2004 Jan; 11(1):167-71. PubMed ID: 14654921 [TBL] [Abstract][Full Text] [Related]
18. Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression. Mishima K; Nariai Y; Yoshimura Y Oral Oncol; 2005 Jan; 41(1):77-81. PubMed ID: 15598589 [TBL] [Abstract][Full Text] [Related]
19. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235 [TBL] [Abstract][Full Text] [Related]
20. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Lin J; Hsiao PW; Chiu TH; Chao JI Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]